Date: 2012-02-06
Type of information: R&D agreement
Compound: software solutions for clinical genomics and personalized medicine
Company: Integromics (USA-Spain) Galician Foundation of Genomic Medicine (FPGMX) (Spain)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: Integromics has entered into a partnership with Professor Carracedo and his team at the Galician Foundation of Genomic Medicine (FPGMX), a recipient of the European Life Technologies ‘Ion Torrent Visionary Winners Award’, for the development of inexpensive solutions for clinical genomics. The interpretation of next generation sequencing (NGS) data has been recognized as a major bottleneck in the adoption of personalized medicine, both in terms of cost and time. The ApliClinics collaboration has been designed to address the issues, at the bench and bioinformatics levels, being faced by the clinical labs trying to apply NGS technology. The project aims to improve procedures and optimize tools to make the use of NGS faster in the routine healthcare environment, which will alleviate the current lack of applications critically needed by clinicians, as well as helping to lessen their workload. The ApliClinics project opens a new field of application for Integromics and represents an ideal opportunity for the company to reinforce its commitment to the development of software solutions for personalized medicine. \"The interest of the group, in addition to genomic research, is the practical translation of next generation sequencing to clinical routine casework,” said Professor Angel Carracedo, director of the FPGMX. “For this reason this project is essential for us. In this moment the bottleneck is not data production but to have bioinformatic tools allowing us to obtain reliable and accurate information of the variation found after DNA sequencing using NGS facilities, which is the main objective of this project. Against this setting, and as NGS develops for specific cases in a broader clinical setting, it is hoped that the findings of the ApliClinics project, in terms of software and lab procedures, will bring low cost NGS technology closer to a clinical reality. Integromics will be looking to announce the first results of the ApliClinics project in Q4 2012.
Financial terms: The new partnership has been awarded a € 1 million grant from the European Regional Development Fund and the Spanish Government for a project entitled ‘Advanced analysis and interpretation of low-cost next generation sequencing data for clinical applications (ApliClinics LC-NGS).
Latest news:
